// App-Quantinova.ai

: Trial in progress: A phase 2, multicenter, open-label study of DKN-01 in combination with tislelizumab and chemotherapy as 1L therapy in patients with unresectable, locally advanced or metastatic gastric or gastroesophageal junction adenocarcinoma (G/GEJ; DisTinGuish).

Researchers

Presenter

  • Keun-Wook Lee

Principal Investigators

  • Markus H. Moehler

  • David Cunningham

  • Zev A. Wainberg

  • Hope Elizabeth Uronis

  • Do-Youn Oh

  • In-Ho Kim

  • Byoung Yong Shim

  • Sun Jin Sym

  • Rachel A Altura

  • Melissa C Stilian

  • Elizabeth C Parker

  • Samuel J Klempner

Medical Centers

  • The Catholic University of Korea, Seoul St. Mary's Hospital, Seoul

  • Chonbuk National University Medical School, Jeonju, Korea, Republic of

  • Seoul National University College of Medicine, Seoul National University Hospital, Seoul, Republic of (South), Korea

  • UCLA Care Center, Los Angeles, CA

  • Division of Medical Oncology, Department of Internal Medicine, Gachon University Gil Medical Center, Inchon, Korea, Republic of (South)

  • Jounce Therapeutics, Cambridge, MA

  • St. Vincent's Hospital, Catholic University of Korea, Suwon, Korea, Republic of (South)

  • Neon Therapeutics, Inc., Cambridge, MA

  • Duke University Medical Center, Durham, NC

  • The Royal Marsden Hospital NHS Foundation Trust, London & Surrey, United Kingdom

  • Johannes-Gutenberg Universitat Mainz, Mainz, Germany

  • Massachusetts General Hospital, Boston, MA

Locations

  • Germany

  • United Kingdom

  • Republic of South Korea

  • United States

Companies

  • Leap Therapeutics, I

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Gastroesophageal junction (GEJ) adenocarcinoma

Biomarkers

  • Programmed death-ligand 1

  • erb-b2 receptor tyrosine kinase 2

  • Human epidermal growth factor receptor 2

Drug/Treatment

  • Tislelizumab

  • mFOLFOX6

  • DKN 01

  • Capecitabine + Oxaliplatin

Outcome

  • N/A

Study Design

  • Randomized

  • Double Blind/Blinded

  • Open Label

  • Multicenteric

Phase

  • II

Study Id's

  • NCT04363801

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved